MTVA

MetaVia is a pre-revenue, clinical-stage cardiometabolic biotech whose own auditors and management flag "substantial doubt about our ability to continue as a going concern within twelve months." The 10-K is explicit that existing cash plus the January 2026 offering funds operations only "into the fourth quarter of 2026" — roughly two to three quarters of runway. With $10.3M cash (down 35.8% YoY), a -$15.7M operating cash burn, and no product revenue in any year on record (FY2021–FY2025 all zero revenue, cumulative losses driving a -$148.8M accumulated deficit), the company must raise dilutive capital again very soon, and it states it has no financing commitments and may not succeed on acceptable terms — or at all. That is the definition of unknowable, uncompensated risk for an equity holder.

The balance sheet is thin rather than levered: $5.79M liabilities against $5.33M equity (1.09x) and current assets of $10.9M vs. $5.65M current liabilities. But equity is being eroded fast (-32.8% YoY) and ROE is -243%. The apparent "improvements" — net loss narrowing 53% to -$13.0M and R&D falling 68% — are not signs of a maturing business; they reflect a shrunken cost base and prior-year charges, not progress toward profitability. The EPS of -$7.35 on just 5.09M shares (down 41% YoY) signals a reverse split and heavy prior dilution; the $1.48 price after that engineering underscores how much value has already been destroyed.